A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.
收藏DataCite Commons2025-01-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007254/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to test the long-term safety and tolerability of SPD476 in the
maintenance of ulcerative colitis remission.
提供机构：
Vivli
创建时间：
2021-07-01
